|
US7935812B2
(en)
|
2002-02-20 |
2011-05-03 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
|
EP1519714B1
(de)
|
2002-06-28 |
2010-10-20 |
Protiva Biotherapeutics Inc. |
Verfahren und vorrichtung zur herstellung von liposomen
|
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
SG190613A1
(en)
|
2003-07-16 |
2013-06-28 |
Protiva Biotherapeutics Inc |
Lipid encapsulated interfering rna
|
|
ES2423060T3
(es)
|
2004-03-12 |
2013-09-17 |
Alnylam Pharmaceuticals, Inc. |
Agentes iRNA que tienen como diana al VEGF
|
|
US7303881B2
(en)
*
|
2004-04-30 |
2007-12-04 |
Pds Biotechnology Corporation |
Antigen delivery compositions and methods of use
|
|
ATE536418T1
(de)
*
|
2004-06-07 |
2011-12-15 |
Protiva Biotherapeutics Inc |
Lipidverkapselte interferenz-rna
|
|
WO2005120152A2
(en)
|
2004-06-07 |
2005-12-22 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use
|
|
EP1773857A4
(de)
|
2004-07-02 |
2009-05-13 |
Protiva Biotherapeutics Inc |
Das immunsystem stimulierende sirna-moleküle und anwendungen davon
|
|
US20060134189A1
(en)
*
|
2004-11-17 |
2006-06-22 |
Protiva Biotherapeutics, Inc |
siRNA silencing of apolipoprotein B
|
|
WO2006074546A1
(en)
*
|
2005-01-13 |
2006-07-20 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
|
US7404969B2
(en)
|
2005-02-14 |
2008-07-29 |
Sirna Therapeutics, Inc. |
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
|
|
WO2007086883A2
(en)
*
|
2005-02-14 |
2007-08-02 |
Sirna Therapeutics, Inc. |
Cationic lipids and formulated molecular compositions containing them
|
|
US20070054873A1
(en)
*
|
2005-08-26 |
2007-03-08 |
Protiva Biotherapeutics, Inc. |
Glucocorticoid modulation of nucleic acid-mediated immune stimulation
|
|
GB2430881B
(en)
*
|
2005-10-06 |
2010-10-13 |
Ntnu Technology Transfer As |
Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity
|
|
WO2007048046A2
(en)
|
2005-10-20 |
2007-04-26 |
Protiva Biotherapeutics, Inc. |
Sirna silencing of filovirus gene expression
|
|
WO2007051303A1
(en)
|
2005-11-02 |
2007-05-10 |
Protiva Biotherapeutics, Inc. |
MODIFIED siRNA MOLECULES AND USES THEREOF
|
|
CN101484588B
(zh)
|
2006-05-11 |
2013-11-06 |
阿尔尼拉姆医药品有限公司 |
抑制pcsk9基因表达的组合物和方法
|
|
US8598333B2
(en)
*
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
|
US7915399B2
(en)
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
|
JP5325576B2
(ja)
*
|
2006-06-30 |
2013-10-23 |
北海道システム・サイエンス株式会社 |
核酸導入用組成物
|
|
EP2057179A4
(de)
*
|
2006-08-24 |
2010-11-10 |
British Columbia Cancer Agency |
Zusammensetzung und verfahren zur behandlung von myelosuppression
|
|
WO2008042973A2
(en)
|
2006-10-03 |
2008-04-10 |
Alnylam Pharmaceuticals, Inc. |
Lipid containing formulations
|
|
JPWO2008087803A1
(ja)
*
|
2007-01-16 |
2010-05-06 |
国立大学法人北海道大学 |
抗酸化成分を封入したイオントフォレーシス用リポソーム製剤
|
|
EP2117304A4
(de)
|
2007-02-07 |
2011-08-24 |
Gradalis Inc |
Verfahren und zusammensetzung zur modulation einer sialsäureproduktion und zur behandlung vererbter einschlusskörper-myopathie
|
|
US8877206B2
(en)
*
|
2007-03-22 |
2014-11-04 |
Pds Biotechnology Corporation |
Stimulation of an immune response by cationic lipids
|
|
GB0707096D0
(en)
*
|
2007-04-12 |
2007-05-23 |
Ntnu Technology Transfer As |
Method
|
|
JP2010187707A
(ja)
*
|
2007-06-12 |
2010-09-02 |
Hokkaido Univ |
インスリンを封入したイオントフォレーシス用リポソーム製剤
|
|
US8716255B2
(en)
|
2007-08-10 |
2014-05-06 |
British Columbia Cancer Agency Branch |
Microrna compositions and methods for the treatment of myelogenous leukemia
|
|
KR100807060B1
(ko)
*
|
2007-08-28 |
2008-02-25 |
고려대학교 산학협력단 |
신규한 양이온성 지질, 그의 제조 방법 및 그를 포함하는전달체
|
|
JP5697988B2
(ja)
|
2007-12-27 |
2015-04-08 |
プロチバ バイオセラピューティクス インコーポレイティッド |
干渉rnaを使用したポロ様キナーゼ発現のサイレンシング方法
|
|
JP5749494B2
(ja)
*
|
2008-01-02 |
2015-07-15 |
テクミラ ファーマシューティカルズ コーポレイション |
核酸の送達のための改善された組成物および方法
|
|
BRPI0907008A2
(pt)
*
|
2008-01-31 |
2015-07-07 |
Alnylam Pharmaceuticals Inc |
Métodos otimizados para liberação de dsrna alvejando o gene pcsk9
|
|
AU2009221775B2
(en)
*
|
2008-03-05 |
2015-05-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
|
AU2009236219B8
(en)
|
2008-04-15 |
2015-06-25 |
Arbutus Biopharma Corporation |
Silencing of CSN5 gene expression using interfering RNA
|
|
NZ588583A
(en)
|
2008-04-15 |
2012-08-31 |
Protiva Biotherapeutics Inc |
Novel lipid formulations for nucleic acid delivery
|
|
WO2009129387A2
(en)
*
|
2008-04-16 |
2009-10-22 |
Abbott Laboratories |
Cationic lipids and uses thereof
|
|
AU2009236306B2
(en)
|
2008-04-17 |
2015-04-02 |
Pds Biotechnology Corporation |
Stimulation of an immune response by enantiomers of cationic lipids
|
|
JP5299424B2
(ja)
|
2008-06-19 |
2013-09-25 |
日本新薬株式会社 |
薬物担体
|
|
EP2326331A4
(de)
*
|
2008-08-18 |
2013-05-15 |
Merck Sharp & Dohme |
Neue lipidnanopartikel und neue komponenten zur freisetzung von nukleinsäuren
|
|
WO2010036962A1
(en)
|
2008-09-25 |
2010-04-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
|
JP5777519B2
(ja)
|
2008-10-09 |
2015-09-09 |
テクミラ ファーマシューティカルズ コーポレイション |
改良されたアミノ脂質および核酸の送達方法
|
|
AU2009307677C1
(en)
|
2008-10-20 |
2022-09-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
|
CA2741373A1
(en)
|
2008-10-30 |
2010-06-03 |
Peixuan Guo |
Membrane-integrated viral dna-packaging motor protein connector biosensor for dna sequencing and other uses
|
|
EP4241767B1
(de)
|
2008-11-10 |
2024-10-23 |
Arbutus Biopharma Corporation |
Neuartige lipide und zusammensetzungen zur verabreichung von therapeutika
|
|
EP2610343A3
(de)
|
2008-11-26 |
2013-09-25 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zum entwurf von sirna und oligoribonukleotide zur hemmung der aktivität des hepatitis-c-virus
|
|
JP5600299B2
(ja)
*
|
2008-11-26 |
2014-10-01 |
中外製薬株式会社 |
ベシクル製剤
|
|
CA2746514C
(en)
|
2008-12-10 |
2018-11-27 |
Alnylam Pharmaceuticals, Inc. |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
|
AU2010223967B2
(en)
*
|
2009-03-12 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
|
GB0904941D0
(en)
*
|
2009-03-23 |
2009-05-06 |
Ntnu Technology Transfer As |
Composition
|
|
GB0904942D0
(en)
|
2009-03-23 |
2009-05-06 |
Ntnu Technology Transfer As |
Composition
|
|
CA2760706C
(en)
*
|
2009-05-05 |
2019-08-06 |
Alnylam Pharmaceuticals, Inc. |
Methods of delivering oligonucleotides to immune cells
|
|
WO2010135207A1
(en)
|
2009-05-16 |
2010-11-25 |
Agave Pharma, Incorporated |
Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules
|
|
TR201811076T4
(tr)
*
|
2009-06-10 |
2018-08-27 |
Arbutus Biopharma Corp |
Geliştirilmiş lipit formulasyonu.
|
|
AU2010260148A1
(en)
|
2009-06-15 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated dsRNA targeting the PCSK9 gene
|
|
US9051567B2
(en)
|
2009-06-15 |
2015-06-09 |
Tekmira Pharmaceuticals Corporation |
Methods for increasing efficacy of lipid formulated siRNA
|
|
US8236943B2
(en)
*
|
2009-07-01 |
2012-08-07 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein B
|
|
US9018187B2
(en)
|
2009-07-01 |
2015-04-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
US8283333B2
(en)
|
2009-07-01 |
2012-10-09 |
Protiva Biotherapeutics, Inc. |
Lipid formulations for nucleic acid delivery
|
|
US8569256B2
(en)
|
2009-07-01 |
2013-10-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
WO2011011447A1
(en)
|
2009-07-20 |
2011-01-27 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing ebola virus gene expression
|
|
EP2464336A4
(de)
|
2009-08-14 |
2013-11-20 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der expression eines gens aus dem ebolavirus
|
|
WO2011022460A1
(en)
|
2009-08-20 |
2011-02-24 |
Merck Sharp & Dohme Corp. |
Novel cationic lipids with various head groups for oligonucleotide delivery
|
|
US9187746B2
(en)
|
2009-09-22 |
2015-11-17 |
Alnylam Pharmaceuticals, Inc. |
Dual targeting siRNA agents
|
|
CA2775092A1
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
DK3252068T3
(da)
|
2009-10-12 |
2025-08-25 |
Larry J Smith |
Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro
|
|
WO2011056682A1
(en)
|
2009-10-27 |
2011-05-12 |
The University Of British Columbia |
Reverse head group lipids, lipid particle compositions comprising reverse headgroup lipids, and methods for the delivery of nucleic acids
|
|
US9101643B2
(en)
|
2009-11-03 |
2015-08-11 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
|
|
CN107028886A
(zh)
|
2009-11-04 |
2017-08-11 |
不列颠哥伦比亚大学 |
含有核酸的脂质粒子及相关的方法
|
|
PL3338765T3
(pl)
*
|
2009-12-01 |
2019-06-28 |
Translate Bio, Inc. |
Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych
|
|
EP2525781A1
(de)
|
2010-01-22 |
2012-11-28 |
Schering Corporation |
Neue kationische lipide zur abgabe von oligonukleotiden
|
|
WO2011109294A1
(en)
*
|
2010-03-01 |
2011-09-09 |
Dicerna Pharmaceuticals, Inc. |
Lipid delivery formulations
|
|
EP2553019A1
(de)
|
2010-03-26 |
2013-02-06 |
Mersana Therapeutics, Inc. |
Modifizierte polymere zur freisetzung von polynukleotiden, verfahren zu ihrer herstellung und verfahren zu ihrer verwendung
|
|
WO2011127255A1
(en)
|
2010-04-08 |
2011-10-13 |
Merck Sharp & Dohme Corp. |
Preparation of lipid nanoparticles
|
|
US10077232B2
(en)
|
2010-05-12 |
2018-09-18 |
Arbutus Biopharma Corporation |
Cyclic cationic lipids and methods of use
|
|
US20130123338A1
(en)
|
2010-05-12 |
2013-05-16 |
Protiva Biotherapeutics, Inc. |
Novel cationic lipids and methods of use thereof
|
|
US8802863B2
(en)
|
2010-05-24 |
2014-08-12 |
Sirna Therapeutics, Inc. |
Amino alcohol cationic lipids for oligonucleotide delivery
|
|
US8748667B2
(en)
*
|
2010-06-04 |
2014-06-10 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
AU2011268146A1
(en)
|
2010-06-17 |
2013-01-10 |
Actogenix Nv |
Compositions and methods for treating inflammatory conditions
|
|
WO2012000104A1
(en)
|
2010-06-30 |
2012-01-05 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
ES2646669T3
(es)
|
2010-07-06 |
2017-12-14 |
Glaxosmithkline Biologicals Sa |
Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
|
|
US11291635B2
(en)
|
2010-07-06 |
2022-04-05 |
Glaxosmithkline Biological Sa |
Virion-like delivery particles for self-replicating RNA molecules
|
|
SI2591114T1
(sl)
|
2010-07-06 |
2016-10-28 |
Glaxosmithkline Biologicals S.A. |
Imunizacija velikih sesalcev z majhnimi odmerki RNA
|
|
US9770463B2
(en)
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
|
AU2011276234B2
(en)
|
2010-07-06 |
2016-02-25 |
Glaxosmithkline Biologicals S.A. |
Liposomes with lipids having an advantageous pKa- value for RNA delivery
|
|
US20130323269A1
(en)
*
|
2010-07-30 |
2013-12-05 |
Muthiah Manoharan |
Methods and compositions for delivery of active agents
|
|
EP2601212A1
(de)
|
2010-08-04 |
2013-06-12 |
Cizzle Biotechnology Limited |
Verfahren und verbindungen zur diagnose und behandlung von
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
KR20130100278A
(ko)
|
2010-08-31 |
2013-09-10 |
머크 샤프 앤드 돔 코포레이션 |
올리고뉴클레오티드의 전달을 위한 신규 단일 화학 존재물 및 방법
|
|
WO2012031043A1
(en)
|
2010-08-31 |
2012-03-08 |
Novartis Ag |
Pegylated liposomes for delivery of immunogen-encoding rna
|
|
TR201908635T4
(tr)
*
|
2010-08-31 |
2019-07-22 |
Glaxosmithkline Biologicals Sa |
Protein kodlayıcı rna?nın lipozomal verilmesine uygun lipitler.
|
|
BR112013004879A2
(pt)
|
2010-08-31 |
2018-04-24 |
Novartis Ag |
lipossomas pequenos para entrega de rna que codifica imunogénio
|
|
US8466122B2
(en)
|
2010-09-17 |
2013-06-18 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
|
MX349088B
(es)
|
2010-09-20 |
2017-07-10 |
Merck Sharp & Dohme |
Lípidos catiónicos novedosos de bajo peso molecular para la entrega de oligonucleótidos.
|
|
KR20130114115A
(ko)
|
2010-09-30 |
2013-10-16 |
머크 샤프 앤드 돔 코포레이션 |
올리고뉴클레오티드 전달을 위한 저분자량 양이온성 지질
|
|
ES3005233T3
(en)
|
2010-10-01 |
2025-03-14 |
Modernatx Inc |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
EP3520813B1
(de)
|
2010-10-11 |
2023-04-19 |
GlaxoSmithKline Biologicals S.A. |
Antigenfreisetzungsplattformen
|
|
CN103153347A
(zh)
|
2010-10-21 |
2013-06-12 |
默沙东公司 |
用于寡核苷酸递送的新型低分子量阳离子脂质
|
|
EP3766975A1
(de)
|
2010-10-29 |
2021-01-20 |
Sirna Therapeutics, Inc. |
Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
|
|
WO2012061259A2
(en)
|
2010-11-05 |
2012-05-10 |
Merck Sharp & Dohme Corp. |
Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
|
|
US8853377B2
(en)
|
2010-11-30 |
2014-10-07 |
Shire Human Genetic Therapies, Inc. |
mRNA for use in treatment of human genetic diseases
|
|
TW201309621A
(zh)
*
|
2011-02-08 |
2013-03-01 |
Daiichi Sankyo Co Ltd |
新穎脂質
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
SG2014010409A
(en)
|
2011-05-10 |
2014-05-29 |
Penn State Res Found |
Ceramide anionic liposome compositions
|
|
DK3336082T3
(da)
|
2011-06-08 |
2020-04-27 |
Translate Bio Inc |
Spaltelige lipider
|
|
PT2717893T
(pt)
|
2011-06-08 |
2019-08-20 |
Translate Bio Inc |
Composições de nanopartículas lipídicas e métodos para transferência de arnm
|
|
EP3854413A1
(de)
|
2011-07-06 |
2021-07-28 |
GlaxoSmithKline Biologicals SA |
Immunogene kombinationszusammensetzungen und ihre verwendung
|
|
EP4014966A1
(de)
*
|
2011-07-06 |
2022-06-22 |
GlaxoSmithKline Biologicals S.A. |
Liposomen mit nützlichem n:p-verhältnis zur freisetzung von rna-molekülen
|
|
SG11201400250UA
(en)
*
|
2011-08-31 |
2014-03-28 |
Novartis Ag |
Pegylated liposomes for delivery of immunogen-encoding rna
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2763701B1
(de)
|
2011-10-03 |
2018-12-19 |
Moderna Therapeutics, Inc. |
Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
|
|
EP2766482B1
(de)
|
2011-10-11 |
2016-12-07 |
The Brigham and Women's Hospital, Inc. |
Mikro-rnas in neurodegenerativen erkrankungen
|
|
US20140328759A1
(en)
|
2011-10-25 |
2014-11-06 |
The University Of British Columbia |
Limit size lipid nanoparticles and related methods
|
|
MY167390A
(en)
|
2011-11-18 |
2018-08-16 |
Alnylam Pharmaceuticals Inc |
Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
|
|
WO2013086373A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
ES3065854T3
(en)
|
2011-12-07 |
2026-05-08 |
Alnylam Pharmaceuticals Inc |
Biodegradable lipids for the delivery of active agents
|
|
JP6182457B2
(ja)
*
|
2011-12-12 |
2017-08-16 |
協和発酵キリン株式会社 |
カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子
|
|
AU2012353463B2
(en)
*
|
2011-12-12 |
2017-08-24 |
Kyowa Hakko Kirin Co., Ltd. |
Lipid nanoparticles containing combinations of cationic lipids
|
|
JP2015501844A
(ja)
|
2011-12-16 |
2015-01-19 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
|
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
DK2817287T3
(da)
|
2012-02-24 |
2019-01-02 |
Arbutus Biopharma Corp |
Trialkyl kationisk lipid og metoder til anvendelse deraf
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US9402816B2
(en)
|
2012-04-19 |
2016-08-02 |
Sima Therapeutics, Inc. |
Diester and triester based low molecular weight, biodegradeable cationic lipids for oligonucleotide delivery
|
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
|
WO2013185067A1
(en)
|
2012-06-08 |
2013-12-12 |
Shire Human Genetic Therapies, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
|
WO2013185069A1
(en)
|
2012-06-08 |
2013-12-12 |
Shire Human Genetic Therapies, Inc. |
Pulmonary delivery of mrna to non-lung target cells
|
|
US10286064B2
(en)
|
2012-06-15 |
2019-05-14 |
Pds Biotechnology Corporation |
Cationic lipid vaccine compositions and methods of use
|
|
JP6108197B2
(ja)
*
|
2012-07-02 |
2017-04-05 |
日油株式会社 |
三級アミノ基含有脂質の製造方法
|
|
TWI672149B
(zh)
|
2012-09-21 |
2019-09-21 |
美商Pds生技公司 |
改良之疫苗組成物及使用方法
|
|
ES2921623T3
(es)
|
2012-11-26 |
2022-08-30 |
Modernatx Inc |
ARN modificado terminalmente
|
|
KR102096014B1
(ko)
|
2012-12-05 |
2020-04-03 |
알닐람 파마슈티칼스 인코포레이티드 |
PCSK9 iRNA 조성물 및 그 사용 방법
|
|
IL239317B
(en)
|
2012-12-12 |
2022-07-01 |
Broad Inst Inc |
Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
EP2968586B1
(de)
|
2013-03-14 |
2018-07-25 |
Translate Bio, Inc. |
Cftr-mrna-zusammensetzungen und zugehörige verfahren sowie verwendungen
|
|
ES2981185T3
(es)
|
2013-03-14 |
2024-10-07 |
Translate Bio Inc |
Métodos para la purificación de ARN mensajero
|
|
ES2882110T3
(es)
|
2013-03-14 |
2021-12-01 |
Translate Bio Inc |
Métodos y composiciones para administrar anticuerpos codificados con ARNm
|
|
WO2014172045A1
(en)
|
2013-03-15 |
2014-10-23 |
The University Of British Columbia |
Lipid nanoparticles for transfection and related methods
|
|
EP4614148A3
(de)
|
2013-03-15 |
2025-12-17 |
Translate Bio, Inc. |
Synergistische verbesserung der abgabe von nukleinsäuren über gemischte formulierungen
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
KR102109188B1
(ko)
|
2013-04-01 |
2020-05-11 |
삼성전자주식회사 |
양이온성 지질을 포함하는 온도민감성 리포좀 및 그의 용도
|
|
CN105793425B
(zh)
|
2013-06-17 |
2021-10-26 |
布罗德研究所有限公司 |
使用病毒组分靶向障碍和疾病的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
MX2015017312A
(es)
|
2013-06-17 |
2017-04-10 |
Broad Inst Inc |
Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas.
|
|
JP6738729B2
(ja)
|
2013-06-17 |
2020-08-12 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
分裂終了細胞の疾患および障害をターゲティングおよびモデリングするための系、方法および組成物の送達、エンジニアリングおよび最適化
|
|
WO2015011633A1
(en)
|
2013-07-23 |
2015-01-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for delivering messenger rna
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
US11224642B2
(en)
|
2013-10-22 |
2022-01-18 |
Translate Bio, Inc. |
MRNA therapy for argininosuccinate synthetase deficiency
|
|
MX2016005239A
(es)
|
2013-10-22 |
2016-08-12 |
Shire Human Genetic Therapies |
Tratamiento con acido ribonucleico mensajero para la fenilcetonuria.
|
|
CA2928040A1
(en)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Cns delivery of mrna and uses thereof
|
|
WO2015061467A1
(en)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Lipid formulations for delivery of messenger rna
|
|
BR112016013547A2
(pt)
|
2013-12-12 |
2017-10-03 |
Broad Inst Inc |
Composições e métodos de uso de sistemas crispr-cas em distúrbios de repetições de nucleotídeos
|
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
|
RU2016128077A
(ru)
|
2013-12-12 |
2018-12-06 |
Те Брод Инститьют Инк. |
Доставка, применение и применения в терапии систем и композиций crispr-cas для лечения обусловленных hbv и вирусных заболеваний и нарушений
|
|
BR112016013213A2
(pt)
|
2013-12-12 |
2017-12-05 |
Massachusetts Inst Technology |
administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para visar distúrbios e doenças usando componentes de administração de partículas
|
|
CN111206032B
(zh)
|
2013-12-12 |
2024-07-19 |
布罗德研究所有限公司 |
用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
WO2015089473A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
WO2015130584A2
(en)
|
2014-02-25 |
2015-09-03 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
|
DK3134131T3
(en)
|
2014-04-23 |
2022-02-07 |
Modernatx Inc |
Nucleic acid vaccines
|
|
JP6571679B2
(ja)
|
2014-04-25 |
2019-09-04 |
トランスレイト バイオ, インコーポレイテッド |
メッセンジャーrnaの精製方法
|
|
US10022455B2
(en)
|
2014-05-30 |
2018-07-17 |
Translate Bio, Inc. |
Biodegradable lipids for delivery of nucleic acids
|
|
EP3154694B1
(de)
|
2014-06-13 |
2025-01-29 |
Children's Medical Center Corporation |
Produkte und verfahren zur isolierung von mitochondrien
|
|
CA2952824C
(en)
|
2014-06-24 |
2023-02-21 |
Shire Human Genetic Therapies, Inc. |
Stereochemically enriched compositions for delivery of nucleic acids
|
|
IL316479A
(en)
|
2014-06-25 |
2024-12-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle compositions for nucleic acid delivery
|
|
CA2953265C
(en)
|
2014-07-02 |
2023-09-26 |
Shire Human Genetic Therapies, Inc. |
Encapsulation of messenger rna
|
|
DK3180426T3
(da)
|
2014-08-17 |
2020-03-30 |
Broad Inst Inc |
Genomredigering ved anvendelse af cas9-nickaser
|
|
WO2016027699A1
(ja)
*
|
2014-08-18 |
2016-02-25 |
日油株式会社 |
核酸送達のためのカチオン性脂質
|
|
EP4137138A1
(de)
|
2014-08-29 |
2023-02-22 |
Alnylam Pharmaceuticals, Inc. |
Verfahren zum behandeln von transthyretin (ttr)-vermittelter amyloidose
|
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
KR20170075742A
(ko)
|
2014-10-02 |
2017-07-03 |
프로티바 바이오쎄라퓨틱스, 인코포레이티드 |
B형 간염 바이러스 유전자 발현을 제거하는 조성물 및 방법
|
|
MA56412A
(fr)
|
2014-12-05 |
2022-05-04 |
Translate Bio Inc |
Thérapie par l'arn messager pour le traitement des maladies articulaires
|
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
|
WO2016094872A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
|
EP3230451B1
(de)
|
2014-12-12 |
2021-04-07 |
The Broad Institute, Inc. |
Geschützte guide-rnas (pgrnas)
|
|
WO2016100974A1
(en)
|
2014-12-19 |
2016-06-23 |
The Broad Institute Inc. |
Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
|
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
|
US10385030B2
(en)
|
2015-01-30 |
2019-08-20 |
Nof Corporation |
Cationic lipid
|
|
JP6929791B2
(ja)
|
2015-02-09 |
2021-09-01 |
デューク ユニバーシティ |
エピゲノム編集のための組成物および方法
|
|
WO2016149508A1
(en)
|
2015-03-19 |
2016-09-22 |
Shire Human Genetic Therapies, Inc. |
Mrna therapy for pompe disease
|
|
US11298326B2
(en)
*
|
2015-03-24 |
2022-04-12 |
Kyowa Kirin Co., Ltd. |
Nucleic acid-containing lipid nanoparticles
|
|
CN107567497A
(zh)
|
2015-04-17 |
2018-01-09 |
库瑞瓦格股份公司 |
Rna的冻干
|
|
WO2016184576A2
(en)
|
2015-05-20 |
2016-11-24 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
|
SG10201910431RA
(en)
|
2015-05-20 |
2020-01-30 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
|
US20180245074A1
(en)
|
2015-06-04 |
2018-08-30 |
Protiva Biotherapeutics, Inc. |
Treating hepatitis b virus infection using crispr
|
|
AU2016279077A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
|
EP3436575A1
(de)
|
2015-06-18 |
2019-02-06 |
The Broad Institute Inc. |
Neuartige crispr-enzyme und -systeme
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
IL293323B2
(en)
|
2015-06-18 |
2024-01-01 |
Massachusetts Inst Technology |
Crispr enzyme mutations reducing off-target effects
|
|
WO2016205745A2
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Cell sorting
|
|
HUE067372T2
(hu)
|
2015-06-29 |
2024-10-28 |
Acuitas Therapeutics Inc |
Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
|
|
HK1248278A1
(zh)
|
2015-07-29 |
2018-10-12 |
Arbutus Biopharma Corporation |
用於使乙型肝炎病毒基因表达沉默的组合物及方法
|
|
JP6896703B2
(ja)
|
2015-07-31 |
2021-06-30 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
TTR関連疾患を治療または予防するためのトランスサイレチン(TTR)iRNA組成物およびその使用方法
|
|
US9856481B2
(en)
|
2015-08-13 |
2018-01-02 |
Ann & Robert H. Lurie Children's Hospital |
MicroRNA treatment of fibrosis
|
|
US11564893B2
(en)
|
2015-08-17 |
2023-01-31 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
US11214800B2
(en)
|
2015-08-18 |
2022-01-04 |
The Broad Institute, Inc. |
Methods and compositions for altering function and structure of chromatin loops and/or domains
|
|
WO2017035278A1
(en)
|
2015-08-24 |
2017-03-02 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
|
|
RS63030B1
(sr)
|
2015-09-17 |
2022-04-29 |
Modernatx Inc |
Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava
|
|
US12241053B2
(en)
|
2015-10-09 |
2025-03-04 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
EP4089175A1
(de)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
|
|
CN108473969B9
(zh)
|
2015-10-14 |
2024-08-23 |
川斯勒佰尔公司 |
用于增强生产的rna相关酶的修饰
|
|
CN109153980B
(zh)
|
2015-10-22 |
2023-04-14 |
布罗德研究所有限公司 |
Vi-b型crispr酶和系统
|
|
EP3368687B1
(de)
|
2015-10-27 |
2021-09-29 |
The Broad Institute, Inc. |
Zusammensetzungen und verfahren gegen krebsspezifische sequenzvariationen
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
RS63986B1
(sr)
|
2015-10-28 |
2023-03-31 |
Acuitas Therapeutics Inc |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
EP3368689B1
(de)
|
2015-10-28 |
2020-06-17 |
The Broad Institute, Inc. |
Zusammensetzungen zur modulierung von immunantworten unter verwendung von immunzellgensignaturen
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
EP4092112A1
(de)
|
2015-11-13 |
2022-11-23 |
PDS Biotechnology Corporation |
Lipide als synthetische vektoren zur verbesserung der antigenverarbeitung und präsentation ex-vivo in der dendritischen zelltherapie
|
|
WO2017095967A2
(en)
|
2015-11-30 |
2017-06-08 |
Duke University |
Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
|
|
EP3383411B1
(de)
|
2015-11-30 |
2025-07-09 |
Sana Biotechnology, Inc. |
Sub-mitochondrielle partikel zur verwendung bei der behandlung metabolischer erkrankungen
|
|
CA3007955A1
(en)
|
2015-12-10 |
2017-06-15 |
Modernatx, Inc. |
Lipid nanoparticles for delivery of therapeutic agents
|
|
US12110490B2
(en)
|
2015-12-18 |
2024-10-08 |
The Broad Institute, Inc. |
CRISPR enzymes and systems
|
|
JP7114465B2
(ja)
|
2015-12-22 |
2022-08-08 |
モデルナティエックス インコーポレイテッド |
薬剤の細胞内送達のための化合物および組成物
|
|
ES3057779T3
(en)
|
2016-01-15 |
2026-03-04 |
Childrens Medical Ct Corp |
Therapeutic use of mitochondria and combined mitochondrial agents
|
|
KR102369898B1
(ko)
|
2016-04-08 |
2022-03-03 |
트랜슬레이트 바이오 인코포레이티드 |
다량체 코딩 핵산 및 그 용도
|
|
EP3443081A4
(de)
|
2016-04-13 |
2019-10-30 |
Duke University |
Crispr/cas9-basierte repressoren zur in-vivo-ausschaltung von gen-targets und verfahren zur verwendung
|
|
SG11201810179RA
(en)
|
2016-04-19 |
2018-12-28 |
Broad Inst Inc |
Novel crispr enzymes and systems
|
|
US20200263190A1
(en)
|
2016-04-19 |
2020-08-20 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
AU2017253107B2
(en)
|
2016-04-19 |
2023-07-20 |
Massachusetts Institute Of Technology |
CPF1 complexes with reduced indel activity
|
|
US12076397B2
(en)
*
|
2016-05-10 |
2024-09-03 |
The Regents Of The University Of Michigan |
Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration
|
|
JP7088911B2
(ja)
|
2016-05-18 |
2022-06-21 |
モデルナティエックス インコーポレイテッド |
リラキシンをコードするポリヌクレオチド
|
|
CN109312313A
(zh)
|
2016-06-13 |
2019-02-05 |
川斯勒佰尔公司 |
用于治疗鸟氨酸转氨甲酰酶缺乏症的信使rna疗法
|
|
US11788083B2
(en)
|
2016-06-17 |
2023-10-17 |
The Broad Institute, Inc. |
Type VI CRISPR orthologs and systems
|
|
US12595478B2
(en)
|
2016-06-29 |
2026-04-07 |
The Broad Institute, Inc. |
Crispr-Cas systems having destabilization domain
|
|
AU2017286980B2
(en)
|
2016-06-30 |
2023-10-26 |
Arbutus Biopharma Corporation |
Compositions and methods for delivering messenger RNA
|
|
US10927383B2
(en)
|
2016-06-30 |
2021-02-23 |
Ethris Gmbh |
Cas9 mRNAs
|
|
EP4275747A3
(de)
|
2016-07-19 |
2024-01-24 |
Duke University |
Therapeutische anwendungen von cpf1-basierter genomeditierung
|
|
WO2018035387A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
WO2018035388A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
MA45999A
(fr)
|
2016-08-22 |
2019-06-26 |
Arbutus Biopharma Corp |
Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
WO2018064208A1
(en)
|
2016-09-28 |
2018-04-05 |
The Broad Institute, Inc. |
Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
|
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
AU2017345766A1
(en)
|
2016-10-21 |
2019-05-16 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
EP4714454A2
(de)
|
2016-10-26 |
2026-03-25 |
Acuitas Therapeutics Inc. |
Lipidnanopartikelformulierungen
|
|
CA3037046A1
(en)
|
2016-10-31 |
2018-05-03 |
University Of Massachusetts |
Targeting microrna-101-3p in cancer therapy
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
AU2018224326B2
(en)
|
2017-02-27 |
2024-01-04 |
Translate Bio, Inc. |
Novel codon-optimized CFTR mRNA
|
|
MA47787A
(fr)
|
2017-03-15 |
2020-01-22 |
Modernatx Inc |
Vaccin contre le virus respiratoire syncytial
|
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
EP3596207B1
(de)
|
2017-03-15 |
2023-12-20 |
The Broad Institute, Inc. |
Neuartige cas13b-orthologe-crispr-enzyme und systeme
|
|
ES3020935T3
(en)
|
2017-03-15 |
2025-05-23 |
Modernatx Inc |
Lipid nanoparticle formulation
|
|
KR20190132405A
(ko)
|
2017-03-15 |
2019-11-27 |
모더나티엑스, 인크. |
치료제의 세포내 전달을 위한 화합물 및 조성물
|
|
CA3056133A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
MA47800A
(fr)
|
2017-03-17 |
2020-01-22 |
Univ Newcastle |
Délivrance par vecteur viral adéno-associé d'un fragment de micro-dystrophine pour traiter la dystrophie musculaire
|
|
US11433026B2
(en)
*
|
2017-03-31 |
2022-09-06 |
University Of Rhode Island Board Of Trustees |
Nanoparticle-induced fusogenicity between liposome and endosome membranes for targeted delivery through endosomal escape
|
|
WO2018187590A1
(en)
|
2017-04-05 |
2018-10-11 |
Modernatx, Inc. |
Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
|
EP3610009A1
(de)
|
2017-04-12 |
2020-02-19 |
The Broad Institute, Inc. |
Neuartige typ-vi-crispr-orthologe und systeme
|
|
WO2018191719A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipid delivery of therapeutic agents to adipose tissue
|
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
US12350368B2
(en)
|
2017-04-14 |
2025-07-08 |
The Broad Institute, Inc. |
Delivery of large payloads
|
|
ES2981244T3
(es)
|
2017-04-28 |
2024-10-07 |
Acuitas Therapeutics Inc |
Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos
|
|
WO2018204777A2
(en)
|
2017-05-05 |
2018-11-08 |
The Broad Institute, Inc. |
Methods for identification and modification of lncrna associated with target genotypes and phenotypes
|
|
ES3052812T3
(en)
|
2017-05-08 |
2026-01-14 |
Flagship Pioneering Innovations V Inc |
Compositions for facilitating membrane fusion and uses thereof
|
|
MX2019013752A
(es)
|
2017-05-16 |
2020-07-20 |
Translate Bio Inc |
Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
|
|
US12297436B2
(en)
|
2017-05-18 |
2025-05-13 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
IL271275B1
(en)
|
2017-06-13 |
2026-04-01 |
Flagship Pioneering Innovations V Inc |
Preparations containing croons and their uses
|
|
US12077501B2
(en)
|
2017-06-14 |
2024-09-03 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
WO2018232357A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna formulations
|
|
US20210228738A1
(en)
|
2017-07-17 |
2021-07-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
|
|
US11639329B2
(en)
|
2017-08-16 |
2023-05-02 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
EP4501322A3
(de)
|
2017-08-17 |
2025-04-16 |
Acuitas Therapeutics, Inc. |
Lipide zur verwendung in lipidnanopartikelformulierungen
|
|
US11542225B2
(en)
|
2017-08-17 |
2023-01-03 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
CA3073851A1
(en)
|
2017-08-31 |
2019-03-07 |
Life Technologies Corporation |
Cationic lipid compositions for tissue-specific delivery
|
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
|
KR20200089656A
(ko)
|
2017-09-19 |
2020-07-27 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법
|
|
AU2018338318B2
(en)
|
2017-09-21 |
2022-12-22 |
Massachusetts Institute Of Technology |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
WO2019071054A1
(en)
|
2017-10-04 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODIFYING THE FUNCTION AND STRUCTURE OF BUCKLES AND / OR CHROMATIN DOMAINS
|
|
WO2019135816A2
(en)
|
2017-10-23 |
2019-07-11 |
The Broad Institute, Inc. |
Novel nucleic acid modifiers
|
|
WO2019089803A1
(en)
|
2017-10-31 |
2019-05-09 |
The Broad Institute, Inc. |
Methods and compositions for studying cell evolution
|
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
|
EP3710039A4
(de)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
Verfahren und zusammensetzungen zur behandlung von krebs durch targeting des clec2d-klrb1-wegs
|
|
AU2018378588A1
(en)
|
2017-12-05 |
2020-06-25 |
Pds Biotechnology Corporation |
Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
|
|
WO2019118806A1
(en)
|
2017-12-14 |
2019-06-20 |
Solid Biosciences Inc. |
Non-viral production and delivery of genes
|
|
US11167043B2
(en)
|
2017-12-20 |
2021-11-09 |
Translate Bio, Inc. |
Composition and methods for treatment of ornithine transcarbamylase deficiency
|
|
WO2019126709A1
(en)
|
2017-12-22 |
2019-06-27 |
The Broad Institute, Inc. |
Cas12b systems, methods, and compositions for targeted dna base editing
|
|
MX2020006800A
(es)
|
2017-12-28 |
2020-09-03 |
Takeda Pharmaceuticals Co |
Lipidos cationicos.
|
|
TWI825057B
(zh)
|
2017-12-28 |
2023-12-11 |
國立大學法人京都大學 |
標的基因改變用組成物
|
|
US12509492B2
(en)
|
2018-01-19 |
2025-12-30 |
Duke University |
Genome engineering with CRISPR-Cas systems in eukaryotes
|
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
|
JP7298850B2
(ja)
|
2018-03-27 |
2023-06-27 |
日油株式会社 |
細胞内動態を改善した新規カチオン性脂質
|
|
BR112020025995A2
(pt)
|
2018-06-18 |
2021-03-23 |
Research Institute At Nationwide Children's Hospital |
administração de microdistrofina músculo-específica por vetor de vírus adeno-associado para tratar a distrofia muscular
|
|
US10736847B2
(en)
|
2018-07-03 |
2020-08-11 |
Becton, Dickinson And Company |
Inverting device for liposome preparation by centrifugation
|
|
WO2020033601A1
(en)
|
2018-08-07 |
2020-02-13 |
The Broad Institute, Inc. |
Novel cas12b enzymes and systems
|
|
US20210317461A1
(en)
|
2018-08-09 |
2021-10-14 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
|
US12421507B2
(en)
|
2018-08-20 |
2025-09-23 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of CRISPR-CAS9
|
|
CN118421617A
(zh)
|
2018-08-24 |
2024-08-02 |
川斯勒佰尔公司 |
用于纯化信使rna的方法
|
|
US12151029B2
(en)
|
2018-09-19 |
2024-11-26 |
Modernatx, Inc. |
PEG lipids and uses thereof
|
|
AU2019345067A1
(en)
|
2018-09-19 |
2021-04-08 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
|
WO2020061367A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
IL281615B2
(en)
|
2018-09-21 |
2026-01-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
MX2021003726A
(es)
*
|
2018-10-01 |
2021-05-13 |
BioNTech SE |
Particulas de arn que comprenden polisarcosina.
|
|
CN113166783B
(zh)
|
2018-10-09 |
2024-10-11 |
不列颠哥伦比亚大学 |
包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法
|
|
US12583816B2
(en)
|
2018-10-18 |
2026-03-24 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
EP3883592A1
(de)
|
2018-11-21 |
2021-09-29 |
Translate Bio, Inc. |
Behandlung von zystischer fibrose durch verabreichung von vernebelter mrna, die cftr codiert
|
|
US11166996B2
(en)
|
2018-12-12 |
2021-11-09 |
Flagship Pioneering Innovations V, Inc. |
Anellovirus compositions and methods of use
|
|
JP7523449B2
(ja)
|
2019-01-11 |
2024-07-26 |
アクイタス セラピューティクス インコーポレイテッド |
活性剤の脂質ナノ粒子送達のための脂質
|
|
WO2020190750A1
(en)
|
2019-03-15 |
2020-09-24 |
Modernatx, Inc. |
Hiv rna vaccines
|
|
WO2020191102A1
(en)
|
2019-03-18 |
2020-09-24 |
The Broad Institute, Inc. |
Type vii crispr proteins and systems
|
|
US20220204994A1
(en)
|
2019-04-05 |
2022-06-30 |
Precision Biosciences, Inc. |
Methods of preparing populations of genetically-modified immune cells
|
|
WO2020236972A2
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
|
KR20220032050A
(ko)
|
2019-06-07 |
2022-03-15 |
스크라이브 테라퓨틱스 인크. |
조작된 casx 시스템
|
|
ES2918001B2
(es)
|
2019-08-14 |
2026-05-13 |
Acuitas Therapeutics Inc |
Nanoparticulas lipidicas mejoradas para el suministro de acidos nucleicos
|
|
MX2022003269A
(es)
|
2019-09-19 |
2022-07-04 |
Modernatx Inc |
Compuestos lipidicos de cola ramificada y composiciones para la administracion intracelular de agentes terapeuticos.
|
|
CA3155015A1
(en)
|
2019-09-19 |
2021-03-25 |
Modernatx, Inc. |
Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2021055609A1
(en)
|
2019-09-20 |
2021-03-25 |
Translate Bio, Inc. |
Mrna encoding engineered cftr
|
|
GB2627644B
(en)
|
2020-03-04 |
2024-11-20 |
Verve Therapeutics Inc |
Method for the preparation of GalNAc-lipid nanoparticle
|
|
EP4121018A4
(de)
|
2020-03-17 |
2024-07-03 |
Genevant Sciences Gmbh |
Kationische lipide zur lipidnanopartikelabgabe von therapeutika an hepatische stellatzellen
|
|
WO2021195218A1
(en)
|
2020-03-24 |
2021-09-30 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
|
|
AU2021244555A1
(en)
|
2020-03-24 |
2022-11-24 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
|
IL296781A
(en)
|
2020-03-30 |
2022-11-01 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
BR112022025586A2
(pt)
|
2020-06-15 |
2023-03-07 |
Res Inst Nationwide Childrens Hospital |
Liberação de vetor de vírus adenoassociado para distrofias musculares
|
|
WO2025056938A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
JP7798855B2
(ja)
|
2020-07-16 |
2026-01-14 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子に使用するためのカチオン性脂質
|
|
WO2022023284A1
(en)
|
2020-07-27 |
2022-02-03 |
Anjarium Biosciences Ag |
Compositions of dna molecules, methods of making therefor, and methods of use thereof
|
|
TW202220637A
(zh)
*
|
2020-08-06 |
2022-06-01 |
美商現代公司 |
製備脂質奈米顆粒之方法
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
WO2022076547A1
(en)
|
2020-10-07 |
2022-04-14 |
Precision Biosciences, Inc. |
Lipid nanoparticle compositions
|
|
KR20230118715A
(ko)
|
2020-10-14 |
2023-08-11 |
조지 메이슨 리서치 파운데이션 인코포레이티드 |
이온화 가능 지질 및 이의 제조 및 사용 방법
|
|
US11771652B2
(en)
|
2020-11-06 |
2023-10-03 |
Sanofi |
Lipid nanoparticles for delivering mRNA vaccines
|
|
CA3200234A1
(en)
|
2020-11-25 |
2022-06-02 |
Daryl C. Drummond |
Lipid nanoparticles for delivery of nucleic acids, and related methods of use
|
|
PE20231178A1
(es)
|
2020-12-03 |
2023-08-01 |
Scribe Therapeutics Inc |
Sistemas crispr tipo v clase 2 disenados por ingenieria
|
|
CN117479963A
(zh)
|
2020-12-18 |
2024-01-30 |
盖纳万科学有限公司 |
Peg脂质和脂质纳米粒子
|
|
TW202245835A
(zh)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
WO2022215036A1
(en)
|
2021-04-08 |
2022-10-13 |
Vaxthera Sas |
Coronavirus vaccine comprising a mosaic protein
|
|
US20240358852A1
(en)
|
2021-04-20 |
2024-10-31 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
|
|
EP4329884A1
(de)
|
2021-04-27 |
2024-03-06 |
Generation Bio Co. |
Nichtvirale dna-vektoren zur expression von anti-coronavirus-antikörpern und verwendungen davon
|
|
WO2022232289A1
(en)
|
2021-04-27 |
2022-11-03 |
Generation Bio Co. |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
|
JP2024523839A
(ja)
|
2021-06-08 |
2024-07-02 |
シーフォー セラピューティクス, インコーポレイテッド |
突然変異体brafを分解する療法薬
|
|
KR20220167770A
(ko)
|
2021-06-11 |
2022-12-21 |
주식회사 나이벡 |
타겟 세포 내로 올리고뉴클레오티드를 전달하기 위한 펩타이드-지질의 결합체를 포함하는 나노입자 및 이를 포함하는 약학적 조성물
|
|
AU2022290278A1
(en)
|
2021-06-11 |
2024-01-04 |
LifeEDIT Therapeutics, Inc. |
Rna polymerase iii promoters and methods of use
|
|
AU2022301302A1
(en)
|
2021-07-01 |
2024-01-25 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
|
WO2023288288A1
(en)
|
2021-07-15 |
2023-01-19 |
Turn Biotechnologies, Inc. |
Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use
|
|
WO2023288287A2
(en)
|
2021-07-15 |
2023-01-19 |
Turn Biotechnologies, Inc. |
Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment
|
|
WO2023288285A1
(en)
|
2021-07-15 |
2023-01-19 |
Turn Biotechnologies, Inc. |
Polycistronic expression vectors
|
|
EP4377459A2
(de)
|
2021-07-30 |
2024-06-05 |
Tune Therapeutics, Inc. |
Zusammensetzungen und verfahren zur modulation der expression von frataxin (fxn)
|
|
WO2023010135A1
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
EP4380576A4
(de)
|
2021-08-03 |
2026-04-29 |
Verve Therapeutics Inc |
Zusammensetzungen und verfahren zur gezielten rna-abgabe
|
|
TW202328445A
(zh)
|
2021-08-03 |
2023-07-16 |
美商艾拉倫製藥股份有限公司 |
甲狀腺素運載蛋白(TTR)iRNA組成物及其使用方法
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
EP4402121A1
(de)
|
2021-09-14 |
2024-07-24 |
Renagade Therapeutics Management Inc. |
Acyclische lipide und verfahren zur verwendung davon
|
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
|
KR20240095525A
(ko)
|
2021-09-21 |
2024-06-25 |
스크라이브 테라퓨틱스 인크. |
조작된 casx 억제 시스템
|
|
EP4419081A1
(de)
|
2021-10-22 |
2024-08-28 |
Sail Biomedicines, Inc. |
Mrna-impfstoffzusammensetzung
|
|
EP4426832A1
(de)
|
2021-11-03 |
2024-09-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Genaue genomeditierung mit retrons
|
|
CN118541346A
(zh)
|
2021-11-08 |
2024-08-23 |
奥纳治疗公司 |
用于递送环状多核苷酸的脂质纳米颗粒组合物
|
|
JP2024542188A
(ja)
|
2021-11-16 |
2024-11-13 |
セイル バイオメディシンズ インコーポレイテッド |
新規イオン化可能な脂質および脂質ナノ粒子ならびにそれらを使用する方法
|
|
KR20240128683A
(ko)
|
2021-11-22 |
2024-08-26 |
세일 바이오메디슨스, 인크. |
신규한 이온화 가능 지질 및 지질 나노입자, 및 이를 사용하는 방법
|
|
KR20240107356A
(ko)
|
2021-11-23 |
2024-07-09 |
세일 바이오메디슨스, 인크. |
박테리아-유래 지질 조성물 및 이의 용도
|
|
CA3242402A1
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2023122080A1
(en)
|
2021-12-20 |
2023-06-29 |
Senda Biosciences, Inc. |
Compositions comprising mrna and lipid reconstructed plant messenger packs
|
|
CA3243054A1
(en)
|
2021-12-23 |
2025-04-08 |
Renagade Therapeutics Management Inc. |
Constrained Lipids and Associated Utilization Processes
|
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
JP2025504404A
(ja)
|
2022-01-14 |
2025-02-12 |
アンジャリウム バイオサイエンシズ エージー |
Viii因子をコードするdna分子の組成物、それを作製する方法、及びその使用方法
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
EP4469063A1
(de)
|
2022-01-27 |
2024-12-04 |
BioNTech SE |
Pharmazeutische zusammensetzungen zur abgabe von herpes-simplex-virus-antigenen und zugehörige verfahren
|
|
CN118922401A
(zh)
|
2022-01-31 |
2024-11-08 |
盖纳万科学有限公司 |
用于脂质纳米颗粒的可电离阳离子脂质
|
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
AU2023235112A1
(en)
|
2022-03-14 |
2024-10-17 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
|
EP4499607A1
(de)
|
2022-03-25 |
2025-02-05 |
Sail Biomedicines, Inc. |
Neue ionisierbare lipide und lipidnanopartikel und verfahren zur verwendung davon
|
|
CA3255225A1
(en)
|
2022-04-04 |
2023-10-12 |
The Regents Of The University Of California |
COMPOSITIONS AND METHODS OF GENETIC COMPLEMENTATION
|
|
WO2023196931A1
(en)
|
2022-04-07 |
2023-10-12 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
|
EP4519438A1
(de)
|
2022-05-05 |
2025-03-12 |
The Board of Trustees of the Leland Stanford Junior University |
Interferierende rna-therapie für pln-r14del-kardiomyopathie
|
|
EP4522726A1
(de)
|
2022-05-09 |
2025-03-19 |
Regeneron Pharmaceuticals, Inc. |
Vektoren und verfahren zur in-vivo-antikörperherstellung
|
|
WO2023218431A1
(en)
|
2022-05-13 |
2023-11-16 |
BioNTech SE |
Rna compositions targeting hiv
|
|
EP4531819A2
(de)
*
|
2022-05-25 |
2025-04-09 |
Akagera Medicines, Inc. |
Lipidnanopartikel zur abgabe von nukleinsäuren und verfahren zur verwendung davon
|
|
WO2023230295A1
(en)
|
2022-05-25 |
2023-11-30 |
BioNTech SE |
Rna compositions for delivery of monkeypox antigens and related methods
|
|
CN119562807A
(zh)
|
2022-05-30 |
2025-03-04 |
生物技术公司 |
用于递送核酸的复合物
|
|
WO2023234250A1
(ja)
|
2022-05-30 |
2023-12-07 |
国立大学法人九州大学 |
アニオン性長鎖脂質を含む皮膚のバリア機能を減弱化させることに用いるための組成物、およびカチオン性長鎖脂質とアニオン性長鎖脂質と薬物を含む複合体を分散した分散液
|
|
US20250333767A1
(en)
|
2022-06-02 |
2025-10-30 |
Scribe Therapeutics Inc. |
Engineered class 2 type v crispr systems
|
|
AU2023283348A1
(en)
|
2022-06-07 |
2025-01-09 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
|
GB2634837A
(en)
|
2022-06-07 |
2025-04-23 |
Scribe Therapeutics Inc |
Compositions and methods for the targeting of PCSK9
|
|
TW202413643A
(zh)
|
2022-06-07 |
2024-04-01 |
美商斯奎柏治療公司 |
用於靶向pcsk9的組合物及方法
|
|
KR20250044484A
(ko)
|
2022-06-24 |
2025-03-31 |
튠 쎄라퓨틱스, 인코포레이티드 |
표적 유전자 억제를 통해 저밀도 지단백질을 감소시키기 위한 조성물, 시스템, 및 방법
|
|
CN120051297A
(zh)
|
2022-06-30 |
2025-05-27 |
因达普塔治疗公司 |
工程化自然杀伤(nk)细胞与抗体疗法的组合及相关方法
|
|
EP4554967A2
(de)
|
2022-07-12 |
2025-05-21 |
Tune Therapeutics, Inc. |
Zusammensetzungen, systeme und verfahren zur gezielten transkriptionsaktivierung
|
|
KR20250054842A
(ko)
|
2022-07-29 |
2025-04-23 |
리제너론 파마슈티칼스 인코포레이티드 |
뇌 및 근육으로의 트랜스페린 수용체(tfr)-매개 전달을 위한 조성물 및 방법
|
|
MA71732A
(fr)
|
2022-08-12 |
2025-05-30 |
Life Edit Therapeutics, Inc. |
Nucléases guidées par arn et fragments actifs, variants associés et procédés d'utilisation
|
|
US20260055426A1
(en)
|
2022-08-19 |
2026-02-26 |
Generation Bio Co. |
CLEAVABLE CLOSED-ENDED DNA (ceDNA) AND METHODS OF USE THEREOF
|
|
CN120435557A
(zh)
|
2022-08-19 |
2025-08-05 |
图恩疗法股份有限公司 |
通过靶向基因阻遏调节乙型肝炎病毒的组合物、系统和方法
|
|
EP4581012A2
(de)
|
2022-08-31 |
2025-07-09 |
Sail Biomedicines, Inc. |
Neue ionisierbare lipide und lipidnanopartikel und verfahren zur verwendung davon
|
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
|
WO2024063789A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
CN120225219A
(zh)
|
2022-09-23 |
2025-06-27 |
生物技术欧洲股份公司 |
用于递送肝期抗原的组合物及相关方法
|
|
AU2023347390A1
(en)
|
2022-09-23 |
2025-04-10 |
BioNTech SE |
Compositions for delivery of plasmodium csp antigens and related methods
|
|
WO2024074211A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
AU2023357320A1
(en)
|
2022-10-06 |
2025-04-17 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
CN120693347A
(zh)
|
2022-11-04 |
2025-09-23 |
瑞泽恩制药公司 |
钙电压门控通道辅助亚基γ1(CACNG1)结合蛋白和CACNG1介导的向骨骼肌的递送
|
|
WO2024102677A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
TW202425959A
(zh)
|
2022-11-08 |
2024-07-01 |
美商歐納醫療公司 |
遞送多核苷酸的脂質及奈米顆粒組合物
|
|
WO2024102434A1
(en)
|
2022-11-10 |
2024-05-16 |
Senda Biosciences, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
JP2025540076A
(ja)
|
2022-12-01 |
2025-12-11 |
ジェネレーション バイオ カンパニー |
核酸、イオン化可能な脂質、ステロール、脂質アンカーポリマー、及びヘルパー脂質を含む脂質ナノ粒子、それらの使用
|
|
WO2024119103A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
JP2025541726A
(ja)
|
2022-12-01 |
2025-12-23 |
ジェネレーション バイオ カンパニー |
細胞標的化のためのステルス脂質ナノ粒子組成物
|
|
IL320873A
(en)
|
2022-12-01 |
2025-07-01 |
Generation Bio Co |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions containing them
|
|
WO2024123134A1
(ko)
|
2022-12-09 |
2024-06-13 |
서울대학교산학협력단 |
B 세포 및 t 세포 내로 mrna를 전달하기 위한 펩타이드 기반 결합체를 포함하는 나노입자 및 이의 용도
|
|
KR20240087591A
(ko)
|
2022-12-09 |
2024-06-19 |
주식회사 나이벡 |
타겟 세포 내로 올리고뉴클레오티드를 전달하기 위한 펩타이드 기반 결합체를 포함하는 나노입자 및 이를 포함하는 약학적 조성물
|
|
EP4637717A1
(de)
*
|
2022-12-23 |
2025-10-29 |
Pfizer Inc. |
Lipidpartikelzusammensetzungen und verfahren zur verwendung davon
|
|
EP4642797A1
(de)
|
2022-12-28 |
2025-11-05 |
BioNTech SE |
Gegen hiv gerichtete rna-zusammensetzungen
|
|
KR20250153793A
(ko)
|
2023-01-27 |
2025-10-27 |
세일 바이오메디슨스, 인크. |
변형된 지질 조성물 및 이의 용도
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024206565A1
(en)
|
2023-03-29 |
2024-10-03 |
Scribe Therapeutics Inc. |
Repressor fusion protein systems
|
|
AU2024248139A1
(en)
|
2023-03-29 |
2025-09-25 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
|
WO2024206676A1
(en)
|
2023-03-29 |
2024-10-03 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of lpa
|
|
EP4698150A1
(de)
|
2023-04-19 |
2026-02-25 |
Sail Biomedicines, Inc. |
Verabreichung von polynukleotiden aus lipidnanopartikeln mit rna und ionisierbaren lipiden
|
|
WO2024220752A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Rna therapeutic compositions
|
|
WO2024220653A1
(en)
|
2023-04-19 |
2024-10-24 |
Gradalis, Inc. |
Compositions and methods for modulating sialic acid production and treating hereditary inclusion body myopathy (hibm)
|
|
WO2024220712A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Vaccine compositions
|
|
AU2024265158A1
(en)
|
2023-05-03 |
2025-11-06 |
BioNTech SE |
Optimized csp variants and related methods
|
|
WO2024228044A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
AU2024266138A1
(en)
|
2023-05-03 |
2025-11-13 |
Manifold Biotechnologies, Inc. |
Methods and compositions for high-throughput protein delivery, screening, and detection
|
|
AU2024269222A1
(en)
|
2023-05-05 |
2025-10-09 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
DE102023001946A1
(de)
|
2023-05-12 |
2024-11-14 |
Friedrich-Schiller-Universität Jena, Körperschaft des öffentlichen Rechts |
Nanopartikel für den Transport von Wirkstoffen mit anionischen Gruppen, Verfahren zu deren Herstellung und deren Verwendung
|
|
WO2025012756A1
(en)
|
2023-07-07 |
2025-01-16 |
Pfizer Inc. |
Amphiphilic tlr7/8 adjuvants and uses thereof
|
|
WO2025024324A1
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
IL325865A
(en)
|
2023-07-21 |
2026-03-01 |
BioNTech SE |
Compositions for administering Plasmodium antigens and related methods
|
|
WO2025024337A1
(en)
|
2023-07-24 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025022367A2
(en)
|
2023-07-27 |
2025-01-30 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
WO2025029835A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating il-2 gene expression
|
|
JP7544425B1
(ja)
|
2023-08-01 |
2024-09-03 |
NOVIGO Pharma株式会社 |
固体粒子分散製剤
|
|
WO2025027089A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thiolipids and uses thereof
|
|
WO2025026545A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thioplipids and uses thereof
|
|
WO2025030154A1
(en)
|
2023-08-03 |
2025-02-06 |
The Trustees Of The University Of Pennsylvania |
Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
|
|
WO2025027579A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
CN121772938A
(zh)
|
2023-08-03 |
2026-03-31 |
百欧恩泰欧洲股份公司 |
用于递送单纯疱疹病毒抗原的药物组合物及相关方法
|
|
CN121866336A
(zh)
|
2023-08-03 |
2026-04-14 |
百欧恩泰欧洲股份公司 |
靶向hiv的rna组合物
|
|
WO2025038494A1
(en)
|
2023-08-11 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
WO2025052278A1
(en)
|
2023-09-05 |
2025-03-13 |
Genevant Sciences Gmbh |
Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2025054556A1
(en)
|
2023-09-07 |
2025-03-13 |
BioNTech SE |
Rna compositions for delivery of mpox antigens and related methods
|
|
AU2024343011A1
(en)
|
2023-09-11 |
2026-03-26 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
WO2025059073A1
(en)
|
2023-09-11 |
2025-03-20 |
Tune Therapeutics, Inc. |
Epigenetic editing methods and systems for differentiating stem cells
|
|
WO2025064850A1
(en)
|
2023-09-22 |
2025-03-27 |
BioNTech SE |
Rna constructs with n-terminal degrons to enhance an immune response
|
|
WO2025072383A1
(en)
|
2023-09-25 |
2025-04-03 |
The Broad Institute, Inc. |
Viral open reading frames, uses thereof, and methods of detecting the same
|
|
AU2024357861A1
(en)
|
2023-10-12 |
2026-04-23 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025083619A1
(en)
|
2023-10-18 |
2025-04-24 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and acive fragments and variants thereof and methods of use
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
TW202539697A
(zh)
|
2023-11-15 |
2025-10-16 |
德商拜恩技術股份公司 |
冠狀病毒疫苗
|
|
WO2025124711A1
(en)
|
2023-12-13 |
2025-06-19 |
BioNTech SE |
Glycolipid compositions
|
|
WO2025129158A1
(en)
|
2023-12-15 |
2025-06-19 |
The Broad Institute, Inc. |
Engineered arc delivery vesicles and uses thereof
|
|
WO2025134066A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
TW202525287A
(zh)
|
2023-12-21 |
2025-07-01 |
德商拜恩技術運輸科技有限責任公司 |
可離子化脂質
|
|
WO2025133105A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Compositions and methods
|
|
WO2025149492A1
(en)
|
2024-01-08 |
2025-07-17 |
BioNTech SE |
Rna encoding an immune inhibitory il-1 family member
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025166325A1
(en)
|
2024-02-02 |
2025-08-07 |
Editas Medicine, Inc. |
MODIFIED GUIDE RNAs
|
|
TW202546224A
(zh)
|
2024-02-12 |
2025-12-01 |
美商生命編輯治療學公司 |
新穎的rna引導之核酸酶及用於聚合酶編輯之蛋白質
|
|
WO2025184508A1
(en)
|
2024-03-01 |
2025-09-04 |
Acuitas Therapeutics, Inc. |
Materials and methods for encapsulating therapeutics in lipid nanoparticles
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|
|
WO2025213138A1
(en)
|
2024-04-05 |
2025-10-09 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
|
|
WO2025213131A1
(en)
|
2024-04-05 |
2025-10-09 |
BioNTech SE |
Rna compositions for delivery of orthopox antigens and related methods
|
|
WO2025240940A1
(en)
|
2024-05-17 |
2025-11-20 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of apolipoprotein c3
|
|
WO2025250808A1
(en)
|
2024-05-29 |
2025-12-04 |
The Brigham And Women’S Hospital, Inc. |
Anti-crispr delivery compositions and methods
|
|
WO2025262460A1
(en)
|
2024-06-21 |
2025-12-26 |
BioNTech SE |
Lipid compositions for nucleic acid delivery
|
|
WO2026003754A1
(en)
|
2024-06-25 |
2026-01-02 |
Life Edit Therapeutics, Inc. |
Novel reverse transcriptases and uses thereof
|
|
WO2026003582A2
(en)
|
2024-06-27 |
2026-01-02 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2026015647A1
(en)
|
2024-07-09 |
2026-01-15 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1
|
|
WO2026015882A1
(en)
|
2024-07-12 |
2026-01-15 |
BioNTech SE |
Hsv antigen fragments and related methods
|
|
WO2026018213A1
(en)
|
2024-07-18 |
2026-01-22 |
Vaxthera Sas |
A broadly protective mosaic vaccine against highly pathogenic avian influenza viruses
|
|
WO2026020171A2
(en)
|
2024-07-19 |
2026-01-22 |
Aera Therapeutics, Inc. |
Chimeric antigen receptor constructs
|
|
WO2026050217A2
(en)
|
2024-08-27 |
2026-03-05 |
Iovance Biotherapeutics, Inc. |
Engineered artificial antigen presenting cells and lipid nanoparticles for tumor infiltrating lymphocyte expansion
|
|
WO2026047603A1
(en)
|
2024-08-28 |
2026-03-05 |
BioNTech SE |
Sars-cov-2 immunogenic compositions
|
|
WO2026057626A1
(en)
|
2024-09-11 |
2026-03-19 |
BioNTech SE |
Peptidoglycan hydrolases having multiple enzymatically active domains
|
|
WO2026057625A1
(en)
|
2024-09-11 |
2026-03-19 |
BioNTech SE |
Peptidoglycan hydrolases having a chap domain with engineered active site
|
|
WO2026064512A1
(en)
|
2024-09-18 |
2026-03-26 |
Generation Bio Co. |
Polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
WO2026064753A1
(en)
|
2024-09-23 |
2026-03-26 |
Tune Therapeutics, Inc. |
Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing
|
|
WO2026068864A1
(en)
|
2024-09-30 |
2026-04-02 |
BioNTech SE |
Engineered ch1 and cl domains for the prevention of chain mispairing
|
|
WO2026082899A2
(en)
|
2024-10-16 |
2026-04-23 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
|
WO2026085495A1
(en)
|
2024-10-18 |
2026-04-23 |
Generation Bio Co. |
Synthetic partially single-stranded nucleic acid compositions and uses and methods therefor
|
|
WO2026088120A1
(en)
|
2024-10-24 |
2026-04-30 |
Pfizer Inc. |
Lipidated tlr7/8 modulators as adjuvants and uses thereof
|
|
WO2026088119A1
(en)
|
2024-10-24 |
2026-04-30 |
Pfizer Inc. |
Lipidated tlr7/8 modulators as adjuvants and uses thereof
|
|
WO2026096919A1
(en)
|
2024-11-01 |
2026-05-07 |
Sail Biomedicines, Inc. |
Novel dipepetide core lipids, lipid carriers, and methods of using thereof
|